<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00533065</url>
  </required_header>
  <id_info>
    <org_study_id>GH-003</org_study_id>
    <secondary_id>EudraCT-Nr. 2005-001315-22</secondary_id>
    <secondary_id>Ethics-commission: 05-052-0605</secondary_id>
    <nct_id>NCT00533065</nct_id>
  </id_info>
  <brief_title>Effects of Donepezil on Deficits Associated With Age-Related Decrease of Growth Hormone</brief_title>
  <acronym>GH-003</acronym>
  <official_title>Effects of the Cholinesterase Inhibitor Donepezil on Organic and Functional Deficits Associated With Age-Related Decrease of Growth Hormone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ludwig Boltzmann Gesellschaft</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ludwig Boltzmann Gesellschaft</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The planned study has two purposes:

        1. It is to provide evidence that the administration of a cholinesterase inhibitor will
           result in an increase of IGF-I (primary variable) and in an increase of the secretion
           growth hormone (secondary variable) that can be maintained throughout the
           treatment-period of one year.

        2. The study also tests the hypothesis that maintenance of increased blood levels of growth
           hormone and IGF-I can stop or delay the age-related changes of body composition
           (secondary variables) .
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum IGF1</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Growth hormone, body composition variables</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">80</enrollment>
  <condition>Elderly</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Donepezil</intervention_name>
    <description>week1 - week12: 1 tablet per day (5mg) week13 - week52: 1 tablet per day (10mg)</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged between 70 and 80 years

        Exclusion Criteria:

          -  Cardiac arrhythmias (sick sinus syndrome, AV block, sino-atrial block),

          -  Treatment with beta-blockers, NSAIDs or cholinergic agonists,

          -  Known hypersensitivity to donepezil hydrochloride, piperidine derivatives or to any
             excipients used in the formulation,

          -  Gastric and duodenal ulcer,

          -  Severe renal and hepatic impairment,

          -  Urinary congestion (prostatic hypertrophy),

          -  Obstructive pulmonary disease (bronchial asthma);
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karl H Tragl, MD</last_name>
    <role>Study Director</role>
    <affiliation>Ludwig Boltzmann Institute of Aging Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ludwig Boltzmann Institute</name>
      <address>
        <city>Vienna</city>
        <zip>1220</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <link>
    <url>http://www.ludwigboltzmann.at/</url>
  </link>
  <verification_date>August 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 19, 2007</study_first_submitted>
  <study_first_submitted_qc>September 19, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2007</study_first_posted>
  <last_update_submitted>August 6, 2009</last_update_submitted>
  <last_update_submitted_qc>August 6, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 7, 2009</last_update_posted>
  <responsible_party>
    <name_title>Karl Heinz Tragl MD</name_title>
    <organization>Ludwig Boltzmann Institute of Aging Research</organization>
  </responsible_party>
  <keyword>Aging</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Donepezil</mesh_term>
    <mesh_term>Cholinesterase Inhibitors</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>July 6, 2010</submitted>
    <returned>August 3, 2010</returned>
    <submitted>April 18, 2012</submitted>
    <returned>May 15, 2012</returned>
    <submitted>November 13, 2012</submitted>
    <returned>December 10, 2012</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

